Israel News App
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Written by
admin
in
6. Business
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS)
following switch…
Continue Reading